Decision letter for "Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade"

Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade

Hematological Oncology ◽

10.1002/hon.2711 ◽

2020 ◽

Vol 38 (3) ◽

pp. 213-222

Author(s):

John Apostolidis ◽

Nihad Mokhtar ◽

Rawan Al Omari ◽

Mohammed Darweesh ◽

Hani Al Hashmi

Keyword(s):

Follicular Lymphoma ◽

Emerging Therapies

Download Full-text

Author response for "Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade"

10.1002/hon.2711/v2/response1 ◽

2019 ◽

Author(s):

John Apostolidis ◽

Nihad Mokhtar ◽

Rawan Al Omari ◽

Mohammed Darweesh ◽

Hani Al Hashmi

Keyword(s):

Follicular Lymphoma ◽

Author Response ◽

Emerging Therapies

Download Full-text

Emerging therapies for the treatment of relapsed or refractory follicular lymphoma

Current Oncology ◽

10.3747/co.23.3405 ◽

2016 ◽

Vol 23 (6) ◽

pp. 407 ◽

Cited By ~ 7

Author(s):

D. MacDonald ◽

A. Prica ◽

S. Assouline ◽

A. Christofides ◽

T. Lawrence ◽

...

Keyword(s):

Follicular Lymphoma ◽

Treatment Options ◽

Subsequent Treatment ◽

The Body ◽

Treatment Preferences ◽

Novel Therapies ◽

Related Factors ◽

Treatment Standard ◽

Emerging Therapies ◽

Signal Transduction Inhibitors

With no treatment standard having been established for relapsed and refractory follicular lymphoma, a number of therapeutic approaches are used in Canada. In patients who relapse early or who eventually become resistant to subsequent treatment, prognosis is poor, and new approaches are needed. A number of novel therapies are being examined in this setting, including monoclonal antibodies, immunoconjugates, immunomodulatory agents, and signal transduction inhibitors. With the body of evidence for those emerging therapies accumulating and the standard upfront treatment changing from rituximab and chop (cyclophosphamide–doxorubicin–vincristine–prednisone) or rituximab and cvp (cyclophosphamide–vincristine–prednisone) to bendamustine and rituximab, treatment decisions in the relapsed and refractory setting have become more complex. The choice of subsequent treatment must consider type of upfront treatment; duration of remission; and patient-related factors such as age, comorbidities, and treatment preferences. This paper summarizes the evidence for novel therapies and proposes recommendations for subsequent treatment options by remission duration after induction and maintenance.

Download Full-text